Cambridge-based, molecular information company, Foundation Medicine Inc. and biopharmaceutical company, Clovis Oncology Inc. of Boulder, CO (Nasdaq:CLVS) entered into a diagnostic collaboration with the intent to develop in-vitro diagnostic testing of select cancer patients most likely to respond to Rucaparib, an orally-administered poly (ADP-ribose) polymerase (PARP) inhibitor targeted for the treatment of patients with cancers predisposed to PARP inhibitor sensitivity.